Making Key Decisions for Efficient and Cost-Effective Biopharmaceutical Drug Development Programs

In today’s biopharmaceutical landscape, financial markets are tighter while speed to market remains a critical factor when making development decisions. Increasingly, biopharmaceutical companies are having to make tough choices when prioritizing development of investigational products in their pipelines. Working with a contract development and manufacturing organization (CDMO), however, can help stakeholders ensure that the design of a product’s development program is efficient and appropriate for the stage/phase of development. This article will address how a biopharmaceutical company can leverage the collaborative efforts with their CMDO partner to understand the implications of certain key development decisions. We will also discuss a few types of decisions companies may want to avoid which may preserve cash or reduce costs in the short term but can have unwelcome effects later.